A Phase I Trial of In Vivo Gene Therapy with the Herpes Simplex Thymidine Kinase/Ganciclovir System for the Treatment of Refractory or Recurrent Ovarian Cancer. Iowa Methodist Medical Center, Des Moines, Iowa
- 10 June 1996
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 7 (9) , 1161-1179
- https://doi.org/10.1089/hum.1996.7.9-1161
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection.Proceedings of the National Academy of Sciences, 1994
- Gene Therapy for the Treatment of Recurrent Pediatric Malignant Astrocytomas with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Childrens Hospital, Los Angeles, CaliforniaHuman Gene Therapy, 1994
- Gene Therapy for the Treatment of Malignant Brain Tumors with In Vivo Tumor Transduction with the Herpes Simplex Thymidine Kinase Gene/Ganciclovir System. Iowa Methodist Medical Center, Des Moines, IowaHuman Gene Therapy, 1994
- In VitroEvidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSVtkRetroviral Gene TherapyHuman Gene Therapy, 1993
- An experimental model of retrovirus gene therapy for malignant brain tumorsJournal of Neurosurgery, 1993
- In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain TumorsScience, 1992
- Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transfered by Retroviral VectorsJNCI Journal of the National Cancer Institute, 1990
- Retrovirus Vectors: Promise and RealityScience, 1989
- Plasmid-Determined Resistance to Antimicrobial AgentsAnnual Review of Microbiology, 1978